Oncolytics Biotech CEO buys more ONCY shares

Oncolytics Biotech Inc. CEO and director Kelly Jared reported buying additional common shares in the open market.

Accepted by SEC EDGAR 02/13/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Oncolytics Biotech Inc. CEO and director Kelly Jared reported buying additional common shares in the open market. On February 11, 2026, he purchased 5,600 common shares at a weighted average price of $0.836, and on February 12, 2026, he bought 29,500 common shares at a weighted average price of $0.842.

The filing notes these were executed through multiple trades at prices ranging from $0.820 to $0.856. After these transactions, Jared directly owns 109,000 Oncolytics Biotech common shares.

Insider Trade Summary

Net Buyer: 35,100 shares

Net Buy 2 txns

Insider Kelly Jared

Role Chief Executive Officer

Bought 35,100 shs ($30K)

Increase in Position 47.5%

Type	Security	Shares	Price	Value
Purchase	Common Shares	29,500	$0.842	$25K
Purchase	Common Shares	5,600	$0.836	$5K

Holdings After Transaction: Common Shares — 109,000 shares (Direct)

Holdings Before and After: Common Shares, 73,900 to 109,000 shares (Direct)

Other Insiders: 8 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oncolytics Biotech (ONCY) report for CEO Kelly Jared?

Oncolytics Biotech reported that CEO and director Kelly Jared made two open-market purchases of common shares in February 2026, adding 5,600 shares on February 11 and 29,500 shares on February 12 at weighted average prices of $0.836 and $0.842, respectively.

How many Oncolytics Biotech (ONCY) shares does CEO Kelly Jared own after the reported trades?

After the reported open-market purchases, CEO Kelly Jared directly owns 109,000 Oncolytics Biotech common shares. This total reflects the addition of 5,600 shares on February 11, 2026, and 29,500 shares on February 12, 2026, as disclosed in the Form 4 filing.

On what dates did Kelly Jared buy Oncolytics Biotech (ONCY) shares and at what prices?

Kelly Jared bought Oncolytics Biotech common shares on February 11 and February 12, 2026. The weighted average prices were $0.836 per share for 5,600 shares on February 11 and $0.842 per share for 29,500 shares on February 12, across multiple trade executions.

What price range is disclosed for Kelly Jared’s Oncolytics Biotech (ONCY) share purchases?

The Form 4 notes that Kelly Jared’s reported share purchases were executed in multiple trades at prices ranging from $0.820 to $0.856 per share. The weighted average prices reported are $0.836 and $0.842 for the February 11 and February 12, 2026 transactions, respectively.

Are Kelly Jared’s Oncolytics Biotech (ONCY) share purchases direct or through an intermediary?

The filing shows Kelly Jared’s ownership as direct, indicated by the “D” ownership code for both transactions. There is no disclosure of indirect ownership structures or intermediaries in the provided data, so the 109,000 common shares are held directly by him.

What transaction code is used for Kelly Jared’s Oncolytics Biotech (ONCY) trades and what does it mean?

Both transactions use code “P,” which the filing describes as a purchase in an open market or private transaction. This confirms that the February 11 and 12, 2026 trades were buy transactions, increasing Kelly Jared’s direct holdings of Oncolytics Biotech common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Jared

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/11/2026		P		5,600	A	$0.836(1)	79,500	D
Common Shares	02/12/2026		P		29,500	A	$0.842(1)	109,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.